2025 Financial Guidance
To advance our strategy and expand our leadership in Fabry and Pompe disease, our financial guidance for 2025 is as follows:
| Total Revenue Growth1 | 17% to 24% |
| Galafold Revenue Growth1 | 10% to 15% |
| Pombiliti + Opfolda Growth1 | 65% to 85% |
| Gross Margin | Mid 80% |
| Non-GAAP Operating Expenses4 | $350M to $370M |
| GAAP Net Income | Positive during H2 2025 |
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。